Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer

Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists.

Saved in:
Bibliographic Details
Main Authors: Ospital, Ignacio A., Táquez Delgado, Mónica Alejandra, Nicoud, Melisa Beatriz, Correa, Michelle F., Borges Fernandes, Gustavo A., Andrade, Isabela W., Lauretta, Paolo, Martínez Vivot, Rocío, Comba, María Betina, Zanardi, María Marta, Speisky, Daniela, Uriburu, Juan L., Fernandes, João P. S., Medina, Vanina A.
Format: Artículo biblioteca
Language:eng
Published: Elsevier 2024
Subjects:CANCER DE MAMA, PROLIFERACION CELULAR, METILPIPERAZINA, HISTAMINA,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/18346
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-18346
record_format koha
spelling oai:ucacris:123456789-183462024-06-28T05:02:00Z Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer Ospital, Ignacio A. Táquez Delgado, Mónica Alejandra Nicoud, Melisa Beatriz Correa, Michelle F. Borges Fernandes, Gustavo A. Andrade, Isabela W. Lauretta, Paolo Martínez Vivot, Rocío Comba, María Betina Zanardi, María Marta Speisky, Daniela Uriburu, Juan L. Fernandes, João P. S. Medina, Vanina A. CANCER DE MAMA PROLIFERACION CELULAR METILPIPERAZINA HISTAMINA Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists. 2024-06-27T12:13:56Z 2024-06-27T12:13:56Z 2024 Artículo Ospital, I. A. Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer [en línea]. Biomedicine & Pharmacotherapy. 2024, 174 ( 116527). doi: 10.1016/j.biopha.2024.116527. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/18346 1950-6007 (online) 0753-3322 (impreso) https://repositorio.uca.edu.ar/handle/123456789/18346 10.1016/j.biopha.2024.116527 eng Acceso abierto http://creativecommons.org/licenses/by-nc/4.0/ application/pdf Elsevier Biomedicine & Pharmacotherapy. 2024, 174 ( 116527)
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
topic CANCER DE MAMA
PROLIFERACION CELULAR
METILPIPERAZINA
HISTAMINA
CANCER DE MAMA
PROLIFERACION CELULAR
METILPIPERAZINA
HISTAMINA
spellingShingle CANCER DE MAMA
PROLIFERACION CELULAR
METILPIPERAZINA
HISTAMINA
CANCER DE MAMA
PROLIFERACION CELULAR
METILPIPERAZINA
HISTAMINA
Ospital, Ignacio A.
Táquez Delgado, Mónica Alejandra
Nicoud, Melisa Beatriz
Correa, Michelle F.
Borges Fernandes, Gustavo A.
Andrade, Isabela W.
Lauretta, Paolo
Martínez Vivot, Rocío
Comba, María Betina
Zanardi, María Marta
Speisky, Daniela
Uriburu, Juan L.
Fernandes, João P. S.
Medina, Vanina A.
Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
description Abstract: The aims of this work were to evaluate the expression of histamine H3 receptor (H3R) in triple negative breast cancer (TNBC) samples and to investigate the antitumoral efficacy and safety of the LINS01 series of H3R an tagonists, through in silico, in vitro, and in vivo approaches. Antitumor activity of LINS01009, LINS01010, LINS01022, LINS01023 was assayed in vitro in 4T1 and MDA-MB-231 TNBC cells (0.01–100 μM), and in vivo in 4T1 tumors orthotopically established in BALB/c mice (1 or 20 mg/kg). Additionally, H3R expression was assessed in 50 human TNBC samples. We have described a higher H3R mRNA expression in basal-like/TNBC tumors vs. matched normal tissue using TCGA Pan-Cancer Atlas data, and a higher H3R expression in human tumor samples vs. peritumoral tissue evidenced by immunohistochemistry associated with poorer survival. Furthermore, while all the essayed compounds showed antitumoral properties, LINS01022 and LINS01023 exhibited the most potent antiproliferative effects by: i) inducing cell apoptosis and suppressing cell migration in 4T1 and MDA-MB-231 TNBC cells, and ii) inhibiting cell growth in paclitaxel-resistant 4T1 cells (potentiating the paclitaxel antiproliferative effect). Moreover, 20 mg/kg LINS01022 reduced tumor size in 4T1 tumor-bearing mice, exhibiting a safe toxicological profile and potential for druggability estimated by ADME calculations. We conclude that the H3R is involved in the regulation of TNBC progression, offering promising therapeutic potential for the novel LINS01 series of H3R antagonists.
format Artículo
topic_facet CANCER DE MAMA
PROLIFERACION CELULAR
METILPIPERAZINA
HISTAMINA
author Ospital, Ignacio A.
Táquez Delgado, Mónica Alejandra
Nicoud, Melisa Beatriz
Correa, Michelle F.
Borges Fernandes, Gustavo A.
Andrade, Isabela W.
Lauretta, Paolo
Martínez Vivot, Rocío
Comba, María Betina
Zanardi, María Marta
Speisky, Daniela
Uriburu, Juan L.
Fernandes, João P. S.
Medina, Vanina A.
author_facet Ospital, Ignacio A.
Táquez Delgado, Mónica Alejandra
Nicoud, Melisa Beatriz
Correa, Michelle F.
Borges Fernandes, Gustavo A.
Andrade, Isabela W.
Lauretta, Paolo
Martínez Vivot, Rocío
Comba, María Betina
Zanardi, María Marta
Speisky, Daniela
Uriburu, Juan L.
Fernandes, João P. S.
Medina, Vanina A.
author_sort Ospital, Ignacio A.
title Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
title_short Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
title_full Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
title_fullStr Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
title_full_unstemmed Therapeutic potential of LINS01 histamine H3 receptor antagonists as antineoplastic agents for triple negative breast cancer
title_sort therapeutic potential of lins01 histamine h3 receptor antagonists as antineoplastic agents for triple negative breast cancer
publisher Elsevier
publishDate 2024
url https://repositorio.uca.edu.ar/handle/123456789/18346
work_keys_str_mv AT ospitalignacioa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT taquezdelgadomonicaalejandra therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT nicoudmelisabeatriz therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT correamichellef therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT borgesfernandesgustavoa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT andradeisabelaw therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT laurettapaolo therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT martinezvivotrocio therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT combamariabetina therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT zanardimariamarta therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT speiskydaniela therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT uriburujuanl therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT fernandesjoaops therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
AT medinavaninaa therapeuticpotentialoflins01histamineh3receptorantagonistsasantineoplasticagentsfortriplenegativebreastcancer
_version_ 1806028968457928704